Biomarin Pharmaceutical (BMRN) Times Interest Earned (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Times Interest Earned came in at $7.45 in Q1 2026, down 90.48% YoY from $78.2 in Q1 2025, and up 120.38% on a QoQ basis from -$36.54 in Q4 2025.
Biomarin Pharmaceutical (BMRN) Times Interest Earned (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Times Interest Earned data on file, last reported at $7.45 in Q1 2026.
- Quarterly Times Interest Earned fell 90.48% year-over-year to $7.45 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.11 (down 64.41% YoY) and the FY2025 annual result came in at $2.25, down 41.23% from the prior year.
- Times Interest Earned grew to $7.45 in Q1 2026, from -$36.54 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $78.2 in Q1 2025 to a low of -$53.49 in Q4 2023.
- A 5-year average of $17.12 and a median of $16.85 in 2023 frame the typical range for Times Interest Earned.
- The widest YoY moves for Times Interest Earned: up 1663.71% in 2023, down 1381.88% in 2023.
- Tracing BMRN's Times Interest Earned over 5 years: stood at -$3.61 in 2022, then sank by 1381.88% to -$53.49 in 2023, then soared by 217.1% to $62.63 in 2024, then sank by 158.33% to -$36.54 in 2025, then surged by 120.38% to $7.45 in 2026.
- The last three Times Interest Earned figures came in at $7.45 (Q1 2026), -$36.54 (Q4 2025), and -$18.1 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 1.74 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.74 |
| Mar 31, 2026 | 7.45 |
| Dec 31, 2025 | -36.54 |
| Sep 30, 2025 | -18.10 |
| Jun 30, 2025 | 72.14 |
| Mar 31, 2025 | 78.20 |
| Dec 31, 2024 | 62.63 |
| Sep 30, 2024 | 36.40 |
| Jun 30, 2024 | 33.38 |
| Mar 31, 2024 | 24.53 |
| Dec 31, 2023 | -53.49 |
| Sep 30, 2023 | 8.08 |
| Jun 30, 2023 | 17.46 |
| Mar 31, 2023 | 16.85 |
| Dec 31, 2022 | -3.61 |
| Sep 30, 2022 | -0.52 |
| Jun 30, 2022 | 10.15 |
| Mar 31, 2022 | 36.08 |
| Dec 31, 2021 | -17.13 |
| Sep 30, 2021 | -13.75 |